When to recommend allogeneic transplant in multiple myeloma.

about

Immunologic approaches for the treatment of multiple myeloma.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges.Chimeric antigen receptor T-cell therapies for multiple myeloma.

P2860

Q38692244-17000610-D570-4AB0-AFB0-8CEB03277FE7 Q38764944-136924E6-1FB6-4480-B7EC-EA3F44CDCC69 Q38979403-3CD44B26-25F5-40BA-947F-3EB8B724C533 Q47776210-85AE4BB1-4A39-4DC8-9589-911645F27DC8

P2860

When to recommend allogeneic transplant in multiple myeloma.

Item

http://www.wikidata.org/entity/Q38491721

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

When to recommend allogeneic transplant in multiple myeloma.

@en

type

Item

label

When to recommend allogeneic transplant in multiple myeloma.

@en

prefLabel

When to recommend allogeneic transplant in multiple myeloma.

@en

P1476

When to recommend allogeneic transplant in multiple myeloma.

@en

P2860

Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

The future of autologous stem cell transplantation in myeloma.

How we manage autologous stem cell transplantation for patients with multiple myeloma

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma

Lenalidomide after stem-cell transplantation for multiple myeloma

A comparison of allografting with autografting for newly diagnosed myeloma.

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

P304

2512-2517

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1052808

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Morie A Gertz

P577

2015-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25989864

http://www.w3.org/2001/XMLSchema#string

When to recommend allogeneic transplant in multiple myeloma.

about

P2860

P2860

When to recommend allogeneic transplant in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P698